Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537310
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-Label Multicenter Dose-Escalation Randomized Phase I Study to Evaluate Safety Pharmacokinetics and Anti-Tumor Activity of RO7567132 as a Single Agent and in Combination With Atezolizumab in Participants With Advanced andor Metastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety pharmacokinetics PK pharmacodynamics PD and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab The study will enroll adult participants with selected locally advanced andor metastatic solid tumors for whom standard therapy does not exist has proven to be ineffective or intolerable or is not acceptable to the participant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None